Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 93, 97.e1-97.e7
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controlsActa Neurologica Scandinavica, 2012
- Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's DiseasePLOS ONE, 2009
- Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studiesActa Psychiatrica Scandinavica, 2009
- mGluR1/5-Dependent Long-Term Depression Requires the Regulated Ectodomain Cleavage of Neuronal Pentraxin NPR by TACENeuron, 2008
- Identification and validation of novel CSF biomarkers for early stages of Alzheimer's diseaseProteomics – Clinical Applications, 2007
- Interaction of the N-Terminal Domain of the AMPA Receptor GluR4 Subunit with the Neuronal Pentraxin NP1 Mediates GluR4 Synaptic RecruitmentNeuron, 2007
- Cerebrospinal fluid proteomic biomarkers for Alzheimer's diseaseAnnals of Neurology, 2006
- Increased hippocampal activation in mild cognitive impairment compared to normal aging and ADNeurology, 2005
- Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive ImpairmentJournal of Internal Medicine, 2004
- Neuronal Pentraxin Receptor, a Novel Putative Integral Membrane Pentraxin That Interacts with Neuronal Pentraxin 1 and 2 and Taipoxin-associated Calcium-binding Protein 49Journal of Biological Chemistry, 1997